Differences in Perceived Quality of Sleep and Satisfaction with Insulin Delivery Device in People With Diabetes

Harsimran Singh PhD,* Michelle Manning MA,* Haidee Sanchez BSc,* Keaton Stoner BS^†, Stephanie Habif EdD MS*

Objective

To examine sleep related implications of new-age diabetes management devices including Basal-IQ technology in people with T1D and T2D.

Method

We analyzed perceived quality of sleep and device-related satisfaction in participants from a diabetes research company’s (dQ&A) 2019 US-based panel.

Results

Participants using the t:slim X2™ insulin pump with Basal-IQ® technology reported significantly better perceived quality of sleep and satisfaction with their insulin delivery device compared to participants using other insulin delivery devices.

Conclusion

Perceived quality of sleep was an important determinant of device-related satisfaction in this sample.

View Abstract

Responsible Use of Basal-IQ Technology

Systems like the t:slim X2 insulin pump with Basal-IQ technology are not substitutes for the active management of diabetes. There are common scenarios in which automated systems cannot prevent a hypoglycemic event. The Basal-IQ feature relies on current CGM sensor readings to function and will not be able to predict glucose levels and suspend insulin delivery if a patient’s CGM is not functioning properly or his/her pump is unable to receive the CGM signal. It’s recommended your patient always uses the components of the pump system (pump, cartridges, CGM, and infusion sets) according to the applicable instructions for use and checks them regularly to make sure they are functioning as expected. Patients should always pay attention to their symptoms, actively monitor and manage glucose levels, and treat according to your recommendations.

* Tandem Diabetes Care, San Diego. †dQ&A - The Diabetes Research Company, San Francisco. ‡ Questionnaire item “My insulin delivery device helps me sleep better at night” was scored on a Likert response scale (1-10) with higher values suggesting better perceived quality of sleep.

References
1. Arora T, Taheri S. Sleep Optimization and Diabetes Control: A Review of the Literature. Diabetes Ther 2015;6(4):425-468.
2. Lee SWH, et al. The impact of sleep amount and sleep quality on glycemic control in type 2 diabetes: A systematic review and meta-analysis. Sleep Med Rev 2017;31:91-101.
3. Schnurbein JV, et al. Sleep and glycemic control in adolescents with type 1 diabetes. Pediatr Diabetes 2018;19(1):143-149.
4. Monzon A, et al. Sleep and type 1 diabetes in children and adolescents: Proposed theoretical model and clinical implications.Pediatr Diabetes 2019;20(1):78-85.
5. American Diabetes Association: Standards of medical care in diabetes. Diabetes Care 2017;40:S1–S135.
6. Perez KM, et al. Sleep in Type 1 Diabetes:Implications for Glycemic Control and Diabetes Management. Curr Diab Rep. 2018;18(2):5.

Important Safety Information

Caution: Federal (USA) law restricts the t:slim X2 insulin pump and the t:slim X2 insulin pump with Basal-IQ technology to sale by or on the order of a physician. The t:slim X2 insulin pump with Basal-IQ technology (the System) consists of the t:slim X2 insulin pump, which contains Basal-IQ technology, and a compatible integrated continuous glucose monitor (iCGM, sold separately). The t:slim X2 insulin pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The t:slim X2 insulin pump can be used solely for continuous insulin delivery and as part of the System. When used with a compatible CGM, the t:slim X2 insulin pump with Basal-IQ technology can be used to suspend insulin delivery based on CGM sensor readings. The pump and the System are indicated for use in individuals 6 years of age and greater. The pump and the System are intended for single patient use. The pump and the System are indicated for use with NovoLog or Humalog U-100 insulin. The System is not indicated for use in pregnant women, people on dialysis, or critically ill patients. Users of the pump and the System must: be willing and able to use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts. The t:slim X2 pump, transmitter, and sensor must be removed before MRI, CT, or diathermy treatment. For additional important safety information, visit www.tandemdiabetes.com/safetyinfo.

Differences in Perceived Quality of Sleep and Satisfaction with Insulin Delivery Device in People With Diabetes

Objective

Method

Results

Conclusion

Software

Information

Disclosures